REGENERON PHARMACEUTICALS, INC.
REGNOther · Large accelerated filer · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B | $8.50B |
| Operating income | $3.58B | $3.99B | $4.05B | $4.74B | $8.95B | $3.58B |
| Net income | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B | $3.51B |
| Total assets | $40.56B | $37.76B | $33.08B | $29.21B | $25.43B | $17.16B |
| Total liabilities | $9.30B | $8.41B | $7.11B | $6.55B | $6.67B | $6.14B |
| Equity | $31.26B | $29.35B | $25.97B | $22.66B | $18.77B | $11.03B |
| EPS (diluted) | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 | $30.52 |
| Shares out. | 108.6M | 115.1M | 113.7M | 113.5M | 112.2M | 115.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 24.9%
- Net margin
- 31.4%
- Return on equity
- 14.4%
- Return on assets
- 11.1%
- Return on capital (ROCE)
- 9.9%
- Liabilities / assets
- 22.9%
- Debt / equity
- 0.30×
- Book value / share
- $287.82
- Revenue growth (YoY)
- 1.0%
- Net income growth (YoY)
- 2.1%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 9.21safe
- Accruals / assets
- −1.2%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 6 good- Operating margin is positive
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Ryan Arthur FDirector | May 1, 2026 | Sell | 5 | $701.76 |
| Ryan Arthur FDirector | Apr 1, 2026 | Sell | 1 | $771.32 |
| Ryan Arthur FDirector | Mar 2, 2026 | Sell | 7 | $777.46 |
| Zoghbi Huda YDirector | Feb 19, 2026 | Option exercise | 1,638 | $376.69 |
| Pitofsky JasonOfficer — SVP Controller | Feb 9, 2026 | Option exercise | 1,000 | $492.00 |
| Ryan Arthur FDirector | Feb 9, 2026 | Sell | 1 | $775.63 |
| Bassler Bonnie LDirector | Jan 7, 2026 | Option exercise | 1,500 | $374.12 |
| Zoghbi Huda YDirector | Jan 2, 2026 | Grant | 155 | $0.00 |
| Thompson Craig B.Director | Jan 2, 2026 | Grant | 155 | $0.00 |
| Sing George LDirector | Jan 2, 2026 | Grant | 155 | $0.00 |
| Guarini KathrynDirector | Jan 2, 2026 | Grant | 155 | $0.00 |
| Schenkein David PDirector | Jan 2, 2026 | Grant | 155 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2.8M | 3.6 | -15.0% |
| Apr 30, 2026 | 3.3M | 4.1 | +15.1% |
| Apr 15, 2026 | 2.8M | 4.4 | +11.5% |
| Mar 31, 2026 | 2.5M | 4.2 | +4.0% |
| Mar 13, 2026 | 2.5M | 4.2 | +7.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsApr 29, 2026
- Results of operationsApr 8, 2026
- Results of operationsJan 30, 2026
- Results of operations · Regulation FD disclosureJan 12, 2026
- Results of operationsOct 28, 2025
- Results of operationsOct 6, 2025
- Results of operationsAug 1, 2025
- Shareholder voteJun 18, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 13F-HRMay 8, 2026
- 4PRIMARY DOCUMENTMay 4, 2026
- SCHEDULE 13GApr 30, 2026
- 10-QApr 29, 2026
- 8-KApr 29, 2026
- ARSApr 24, 2026
- DEFA14ADEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALSApr 24, 2026
- DEF 14ADEFINITIVE PROXY STATEMENTApr 24, 2026
- 8-KFORM 8-KApr 8, 2026
- 4OWNERSHIP DOCUMENTApr 3, 2026
- SCHEDULE 13G/AMar 27, 2026
- 4PRIMARY DOCUMENTMar 3, 2026
- 4PRIMARY DOCUMENTFeb 23, 2026
- 144Feb 19, 2026
- 4PRIMARY DOCUMENTFeb 11, 2026
Event-driven situations (3)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.